Skip to main content
SpringerLink
Log in

A phase II clinical study of mAMSA in small cell carcinoma of the lung

  • Short Communication
  • mAMSA Lung Carcinoma
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Thirteen patients with small cell carcinoma of the bronchus that had become resistant to conventional chemotherapy were given 4′-(9-acridinylamino) methanesulphon-m-anisidide (mAMSA) at a dose of 90 or 120 mg/m2 at 3-week intervals. Twenty percent of the courses at 90 mg/m2 produced marked myelosuppression. No responses were observed. Median survival from the start of treatment with mAMSA was 5 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Arlin ZA, Sklaroff RB, Gee TS, Kempin SJ, Howard J, Clarkson BD, Young CW (1980) Phase I and II trial of 4′-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukaemia. Cancer Res 40: 3304

    Google Scholar 

  2. Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer 10: 539

    Google Scholar 

  3. Casper ES, Gralla RJ, Kelsen DP, Lynch GR, Young CW, Golbey B (1980) Phase II studies in non-small cell lung cancer. In: Hansen HH, Dombernowsky P (eds) Abstracts of the II World Conference on Lung Cancer, Copenhagen. Excerpta Medica, Amsterdam, p 225

    Google Scholar 

  4. Cysyk RL, Shoemaker D, Adamson RH (1977) The pharmacologic disposition of 4′-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats. Drug Metab Dispos 5: 579

    Google Scholar 

  5. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN, Boley GP (1979a) Phase 11 study of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep 63: 1961

    Google Scholar 

  6. Legha SS, Latreille J, McCredie KB, Bodey GP (1979b) Neurological and cardiac rhythm abnormalities associated with 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy. Cancer Treat Rep 63: 2001

    Google Scholar 

  7. Schneider RJ, Woodcock TM, Yagoda A (1980) Phase II trial of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma. Cancer Treat Rep 64: 183

    Google Scholar 

  8. Von Hoff DD, Howser D, Gormley P, Bender RA, Glaubiger D, Levine AS, Young RC (1978) Phase I study of methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl) (mAMSA) using a single dose schedule. Cancer Treat Rep 62: 1421

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medicine, Royal Marsden Hospital, SM2 5PT, Sutton, Surrey, Great Britain

    P. J. Dady, A. -P. Sappino, A. Rudd & I. E. Smith

Authors
  1. P. J. Dady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. -P. Sappino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Rudd
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. E. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dady, P.J., Sappino, A.P., Rudd, A. et al. A phase II clinical study of mAMSA in small cell carcinoma of the lung. Cancer Chemother. Pharmacol. 6, 195–196 (1981). https://doi.org/10.1007/BF00262342

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262342

Keywords

Search

Navigation